Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin, Paclitaxel, Gemcitabine, Cisplatin, and Radiation in Urothelial Malignancy
NCT00055835Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Nov 2002
- Primary completion
- Jun 2006
- Modality
- Nanoparticles, DNA Intercalators/Alkylators, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin, Paclitaxel Micelles for Injection, gemcitabine and Cisplatin micelle injection (HA132) in bladder cancer and urethral cancer, sponsored by SWOG Cancer Research Network. Primary endpoint: Overall Survival at 5 years. Started Nov 2002; status: completed.
02
Drugs
carboplatinPaclitaxel Micelles for InjectiongemcitabineCisplatin micelle injection (HA132)
03
Conditions
bladder cancerurethral cancer
Beyond the preview
Go deeper on NCT00055835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00055835.